Search results
Showing 961 to 975 of 1516 results for patients and public
This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.
This quality standard covers assessing, diagnosing and managing head and neck cancer, including cancer of the upper aerodigestive tract in people aged 16 or over. It describes high-quality care in priority areas for improvement.
Advocacy services for adults with health and social care needs (NG227)
This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.
People can comment on our guidance at specific stages in its development.
People can comment on our guidance at specific stages in its development.
In development Reference number: GID-TA11422 Expected publication date: TBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]
In development Reference number: GID-TA11071 Expected publication date: TBC
In development Reference number: GID-TA11584 Expected publication date: 08 December 2027
Awaiting development Reference number: GID-TA11538 Expected publication date: TBC
In development Reference number: GID-TA11130 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 18 February 2026.
In development Reference number: GID-TA11694 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 20 February 2026.
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.